This week, Denali Therapeutics (DNLI) shares have drifted modestly, moving mostly in line with recent trends in the biotech sector. The stock’s performance over the past month reflects a 6% gain, which has outpaced many of its pharmaceutical peers.

Denali Therapeutics’ share price is rallying back after a tough start to 2024. A 14% gain over the past three months hints that investors may be warming up to its growth story. While the 1-year total shareholder return is still down sharply, the recent uptrend signals that sentiment around the stock could be stabilizing after a long period of weakness.

If you’re curious where the next turnaround story might emerge in biotech, it is a great moment to explore other health sector standouts using our See the full list for free.

The recent gains raise a key question for investors: has Denali Therapeutics’ rebound left its shares undervalued compared to future growth potential, or is the market already factoring in everything ahead? Could this be a true buying opportunity?

Price-to-Book Ratio of 2.3x: Is it justified?

Denali Therapeutics is currently trading at a price-to-book (P/B) ratio of 2.3x, which suggests the stock is valued below peer averages based on this metric. At the last close of $16.28, this ratio shows the market is pricing Denali’s net assets less aggressively than many competitors.

The price-to-book ratio compares a company’s market capitalization to its net asset value (assets minus liabilities). For biotechs like Denali Therapeutics, this multiple is a key yardstick because these companies often have limited current earnings but significant intellectual property and R&D investments on their balance sheet.

This P/B of 2.3x is noticeably below the peer average of 5.1x and just under the broader US Biotechs industry average of 2.5x. This may indicate investors are cautious about Denali’s current profitability or ability to unlock value from its assets. The ratio also signals a potential undervaluation for those who believe in a turnaround or major breakthrough.

Result: Price-to-Book Ratio of 2.3x (UNDERVALUED)

However, ongoing net losses and previous underperformance could limit Denali’s upside if revenue momentum does not result in consistent profitability.

Another View: Discounted Cash Flow Signals Overvaluation

Looking from a different angle, our DCF model places Denali Therapeutics’ fair value at just $3, well below its current price of $16.28. This suggests the market may be overestimating near-term growth or not sufficiently accounting for ongoing losses. Which view better captures reality: assets on paper, or cash flow paths ahead?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denali Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 845 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Denali Therapeutics Narrative

If you see things differently or want to investigate Denali Therapeutics on your own terms, it is simple to craft your own story in just a few minutes, Do it your way.

A great starting point for your Denali Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Smart investors do not wait for opportunities to come to them. Spotlight fresh trends, pick up on market momentum, and set your portfolio apart using these curated stock ideas:

• Supercharge your returns with consistent income opportunities by tapping into these 20 dividend stocks with yields > 3% with yields above 3%.
• Ride the AI wave by checking out these 27 AI penny stocks, leading advancements in artificial intelligence across industries such as healthcare and automation.
• Capture tomorrow's winners early by following these 3587 penny stocks with strong financials with strong financials and untapped upside potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.